Accordingly, in RR-MS patients, the CSF levels of the anti-inflammatory molecule IL-13 have been associated with increased SICI, possibly contributing to restored inhibitory synaptic activity and limiting the impact of excitotoxicity. Here, IL13 is linked to myeloid sarcoma.